secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2022-06-17T23:59:59+00:00
Accession:  0001171843-22-004406
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Corvus shareholders elect all director nominees, ratify auditor, approve say-on-pay
--------------------------------------------------------------------------------

- Elected Class III directors: Ian T. Clark (20.9M for), Elisha Gould III (22.6M for), Peter Thompson (17.1M for).
- Ratified PricewaterhouseCoopers as fiscal 2022 auditor with 35.3M votes for.
- Advisory vote on executive compensation approved (22.6M for, 0.4M against).
- Shareholders selected 1-year frequency for future say-on-pay votes (22.5M for 1 year).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000117184322004406/0001171843-22-004406-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000117184322004406/f8k_061722.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-004406

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer